Verastem (VSTM) announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in ...

Goldman Sachs analyst Bruce Lu downgraded UMC (UMC) to Sell from Neutral with a price target of NT$40.50, down from NT$44.50 as part of a broader research note citing “heightened” appreciation of ...